Tetracycline antibiotics: Potential anticancer drugs

• Published in: European journal of pharmacology Vol. 956; p. 175949
• Main Authors: Li, Jiayu, Qin, Yuan, Zhao, Chenhao, Zhang, Zhi, Zhou, Zhiruo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 05.10.2023
• Subjects: Anticancer; Doxycycline; Minocycline; Tetracycline antibiotics; Tigecycline; Minocycline; Tetracycline antibiotics; Tigecycline; Anticancer; Doxycycline
• ISSN: 0014-2999; 1879-0712; 1879-0712
• DOI: 10.1016/j.ejphar.2023.175949

In recent years, research on tetracycline antibiotics has gradually shifted from their antibacterial effects to anticancer effects. Doxycycline, minocycline, and tigecycline as the US Food and Drug Administration (FDA) approved tetracycline antibiotics have been the main subjects of studies. Evidence indicated that they have anticancer properties and are able to control cancer progression through different mechanisms, such as anti-proliferation, anti-metastasis, and promotion of autophagy or apoptosis. In addition, studies have shown that these three tetracycline antibiotics can be utilized in conjunction with chemotherapeutic and targeted drugs to inhibit cancer progression and improve the quality of patient survival. Therefore, doxycycline, minocycline, and tigecycline are taken as examples in this work. Their mechanisms of action in different cancers and related combination therapies are introduced. Their current roles in alleviating the suffering of patients undergoing chemotherapy when used as adjuvant drugs in clinical treatment are also described. Finally, the research gaps and potential research directions at this stage are briefly summarized.